<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of diabetic neuropathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of diabetic neuropathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of diabetic neuropathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eva L Feldman, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Distal symmetric polyneuropathy (DSPN), often considered synonymous with the term "diabetic neuropathy," is the most common neurologic complication of diabetes and a major cause of morbidity. Diabetic neuropathy leads to gradual loss of integrity of the longest nerve fibers, with symptoms beginning distally and symmetrically in the toes and feet. In addition to neurologic disability related to sensory loss and risk of foot ulcers and amputations, approximately 15 to 20 percent of patients have painful symptoms that can further limit function and decrease quality of life.</p><p>Patients with diabetic neuropathy should be treated with a systematic, stepwise approach that includes glycemic control and control of the metabolic syndrome, education and counseling on foot care and safety measures, and symptomatic treatment of pain, when present.</p><p>Management of DSPN is reviewed here. The evaluation, diagnosis, and management of other forms of neuropathy in patients with diabetes, including autonomic neuropathy, are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5275.html" rel="external">"Epidemiology and classification of diabetic neuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5272.html" rel="external">"Screening for diabetic polyneuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5285.html" rel="external">"Diabetic autonomic neuropathy"</a>.)</p><p class="headingAnchor" id="H3549631014"><span class="h1">PREVENTIVE CARE</span><span class="headingEndMark"> — </span>Established, symptomatic diabetic neuropathy is generally not reversible, and management aims to slow further progression and prevent complications, including diabetic foot ulcers, arthropathy, and falls.</p><p class="headingAnchor" id="H2"><span class="h2">Glycemic control</span><span class="headingEndMark"> — </span>The role and importance of glucose control for slowing the progression of neuropathy and other microvascular complications of diabetes vary by type of diabetes.</p><p>In patients with type 1 diabetes, high-quality evidence supports the recommendation to aim for stable and optimal glycemic control in the management of patients with diabetic neuropathy [<a href="#rid1">1</a>]. Long-term follow-up of the landmark Diabetes Control and Complications Trial (DCCT) demonstrated that more intensive glucose control ameliorated the onset of neuropathy as well as progression of surrogate electrophysiologic markers of neuropathy  (<a class="graphic graphic_figure graphicRef70945" href="/z/d/graphic/70945.html" rel="external">figure 1</a>) [<a href="#rid2">2,3</a>]. In a meta-analysis of DCCT and one additional trial in a total of 1228 patients with type 1 diabetes, enhanced glucose control lowered the annualized risk of neuropathy (absolute risk difference -1.8 percent, 95% CI -2.6 to -1.1), the incidence of clinical neuropathy after five years (8 versus 17 percent; relative risk [RR] 0.46, 95% CI 0.33-0.63), and the progression of surrogate measures of neuropathy, including nerve conduction velocity and vibration perception thresholds [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a>.)</p><p>In patients with type 2 diabetes, glucose control has a more modest effect on the course of neuropathy. A meta-analysis of four trials in 6669 patients with type 2 diabetes found a nonsignificant trend toward a small reduction in the annualized risk of neuropathy with enhanced glucose control (-0.58 percent, 95% CI -1.4 to 0.01) [<a href="#rid4">4</a>]. The lack of a larger independent effect of glucose control may reflect a difference in the pathophysiology of neuropathy in type 2 diabetes, which may relate to components of the metabolic syndrome collectively [<a href="#rid5">5</a>]. As in all patients with type 2 diabetes, treatment should focus on multiple patient-centered targets to normalize lipids, blood pressure, weight, and glucose, along with lifestyle modifications to achieve a healthy diet and regular exercise [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Multifactorial risk factor reduction'</a>.)</p><p class="headingAnchor" id="H1943645322"><span class="h2">Risk factor modification</span><span class="headingEndMark"> — </span>Lifestyle interventions are endorsed as an essential practice to prevent onset and progression of neuropathy, particularly in individuals with prediabetes and type 2 diabetes [<a href="#rid1">1,6</a>]. Goals include achieving a normal bodyweight and attaining individualized glycemic, blood pressure, and lipid goals along with 150 minutes of moderate-to-vigorous aerobic activity and two to three sessions of resistance training weekly [<a href="#rid7">7</a>]. In a systematic review of 20 clinical trials, exercise was associated with improvements in function, nerve conduction velocities, and glycemic control in patients with diabetic neuropathy [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/1765.html" rel="external">"Nutritional considerations in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1766.html" rel="external">"Nutritional considerations in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1777.html" rel="external">"Exercise guidance in adults with diabetes mellitus"</a>.)</p><p>Available data suggest that surgical treatment of type 2 diabetes (ie, bariatric surgery) has the potential to reduce neuropathy incidence along with other microvascular complications [<a href="#rid9">9,10</a>]. In a retrospective case-control study of over 15,000 obese adults with type 2 diabetes, bariatric surgery was associated with a lower rate of neuropathy at five years (7 versus 21 percent) [<a href="#rid10">10</a>]. Rates of retinopathy and nephropathy were also lower in the surgical patients. The outcomes of bariatric surgery are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/90469.html" rel="external">"Outcomes of bariatric surgery"</a>.)</p><p>Vascular risk factor treatment is also endorsed to slow or prevent the progression of diabetic neuropathy, including improved control of blood pressure, lipids, avoidance of cigarette smoking, and avoidance of excess alcohol consumption [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Foot care</span><span class="headingEndMark"> — </span>Peripheral neuropathy is one of the most important risk factors for ulcers and amputations in patients with diabetes. Foot care in patients with neuropathy is essential to help lower risk of complications.</p><p>On a daily basis, patients should inspect their feet for the presence of dry or cracking skin, fissures, plantar callus formation, and signs of early infection between the toes and around the toenails. Regular clinical foot examinations to detect peripheral neuropathy are also an essential component of preventive care in all patients with diabetes. (See  <a class="medical medical_review" href="/z/d/html/1749.html" rel="external">"Evaluation of the diabetic foot"</a> and  <a class="medical medical_review" href="/z/d/html/8175.html" rel="external">"Management of diabetic foot ulcers"</a>.)</p><p class="headingAnchor" id="H78418748"><span class="h2">Safety and falls</span><span class="headingEndMark"> — </span>Patients with diabetic neuropathy are at increased risk for gait instability and falls due to progressive loss of proprioception, foot pain, orthostatic hypotension due to autonomic dysfunction, age-related functional impairments, and medication side effects [<a href="#rid1">1</a>]. Although not well studied in this specific patient population, multifaceted interventions including home-based exercise, physical and occupational therapy, and home safety evaluation have been shown to reduce fall risk in older adults and should be considered for patients with gait and balance abnormalities on neurologic examination  (<a class="graphic graphic_algorithm graphicRef69682" href="/z/d/graphic/69682.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3014.html" rel="external">"Falls: Prevention in community-dwelling older persons", section on 'Preventing falls'</a>.)</p><p>Additional safety precautions in patients with diabetic neuropathy may include handlebars in the bathroom and shower, use of nightlights to improve visibility, and testing water temperature with an elbow or uninvolved body part before entering a bath or shower to avoid scalding injury.</p><p class="headingAnchor" id="H4000908919"><span class="h2">B12 deficiency</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> reduces intestinal absorption of B12, and the prevalence of borderline or low B12 levels in metformin-treated patients approaches 20 percent at five years [<a href="#rid11">11</a>]. Patients on metformin with worsening neuropathy symptoms should be screened for B12 deficiency, particularly if examination findings are atypical or suddenly worsening. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Vitamin B12 deficiency'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">PAIN MANAGEMENT</span><span class="headingEndMark"> — </span>Approximately 15 to 20 percent of patients with diabetic neuropathy have pain in the feet, often described as burning or stabbing, as a symptom of small myelinated fiber involvement  (<a class="graphic graphic_table graphicRef118369" href="/z/d/graphic/118369.html" rel="external">table 1</a>) [<a href="#rid12">12,13</a>]. While pain may be self-limited and spontaneously resolve within a year of onset in up to half of patients [<a href="#rid14">14</a>], others have persistent symptoms and disability related to pain. Symptomatic therapies for neuropathic pain are an important component of care in such patients. Pain medications are not useful for nonpainful symptoms of neuropathy, such as numbness.</p><p class="headingAnchor" id="H1815763146"><span class="h2">Initial pharmacotherapy</span></p><p class="headingAnchor" id="H2056659147"><span class="h3">Choice of agent</span><span class="headingEndMark"> — </span>First-line pharmacotherapy options for painful diabetic neuropathy include several antidepressants (eg, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> and other tricyclic drugs) and the gabapentinoid antiseizure medications (<a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>) [<a href="#rid15">15-17</a>]. <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">Capsaicin</a> can also be used but is generally poorly tolerated.</p><p>The available evidence suggests that all are better than placebo in patients with diabetic neuropathy and that comparative efficacy is similar, although few high-quality comparative trials have been done [<a href="#rid18">18-21</a>]. Side effects, dosing frequency, cost, and regulatory approval status may vary. In the United States, three of these medications are approved by the US Food and Drug Administration (FDA) for the indication of diabetic neuropathy (<a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, and the <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> patch [8%]).</p><p>Selection of a specific agent should therefore be individualized based on comorbidities  (<a class="graphic graphic_table graphicRef126209" href="/z/d/graphic/126209.html" rel="external">table 2</a>), drug interactions, side effect profiles, and cost. In practice, comorbidities and concurrent medications often favor one class or another (ie, an antidepressant or a gabapentinoid) in an individual patient, and then the narrower choice within a class is influenced by the patient's age, preferences with regard to dosing frequency, side effects, and cost/formulary considerations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>When comorbidities favor an antidepressant</strong> – Among the first-line options, a serotonin-norepinephrine reuptake inhibitor (SNRI; <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) is a common choice for patients of any age who are not already taking an antidepressant, as these two drugs are generally well tolerated and taken once daily. Some clinicians prefer duloxetine over venlafaxine based on FDA approval status, but most consider them interchangeable when confronted with cost/formulary differences. For younger patients without a cardiac history, a tricyclic antidepressant (TCA) is considered an equally reasonable alternative to an SNRI and may be preferred in a patient with difficulty sleeping, for example, as the drowsy side effects of the TCAs may alleviate insomnia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When comorbidities favor a gabapentinoid</strong> – When a gabapentinoid is favored based on a relevant comorbidity (eg, restless legs syndrome), the choice between <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> is also individualized. The two drugs are similar in their side effect profiles and requirement for renal dosing; differences include FDA approval status for diabetic neuropathy, dosing frequency, and sometimes cost.</p><p></p><p class="headingAnchor" id="H236124"><span class="h3">Administration and efficacy</span></p><p class="headingAnchor" id="H3197642673"><span class="h4">Duloxetine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">Duloxetine</a>, an SNRI, is a first-line treatment option for neuropathic pain in patients with diabetic neuropathy [<a href="#rid1">1,17,22</a>]. It also has efficacy for the treatment of depression, anxiety, and fibromyalgia. The pain modulatory effect is thought to be mediated primarily by synaptic norepinephrine and effects on central perception of pain [<a href="#rid23">23</a>].</p><p>The recommended starting dose of <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> in patients with diabetic neuropathy is 20 to 30 mg daily [<a href="#rid1">1</a>]. The dose can be gradually titrated upwards based on response and tolerability to a maximum of 60 to 120 mg daily. Pain improvement may be seen as early as the first week of treatment [<a href="#rid24">24-26</a>].</p><p>Patients are encouraged to take the drug on a full stomach to reduce risk of nausea. <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">Duloxetine</a> should not be taken with other serotonin or norepinephrine uptake inhibitors (including tricyclic drugs) but can be combined with <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>.</p><p>Common side effects of <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> include nausea, somnolence, dizziness, decreased appetite, constipation, diaphoresis, and sexual dysfunction. Duloxetine and other SNRIs can exacerbate restless legs syndrome, which is common in patients with peripheral neuropathy and can further disrupt sleep. (See  <a class="medical medical_review" href="/z/d/html/4892.html" rel="external">"Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Duloxetine'</a>.)</p><p>A 2014 systematic review identified eight randomized trials of <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> for painful diabetic neuropathy in a total of 2728 patients [<a href="#rid27">27</a>]. For duloxetine 60 mg daily, a 50 percent or greater reduction in pain at 12 weeks was more likely with duloxetine than placebo (45 versus 26 percent; relative risk [RR] 1.73, 95% CI 1.44-2.08). In trials that included an 11-point Likert score scale to measure pain, duloxetine reduced the mean pain score by approximately 1 point more than placebo by 12 weeks. Across trials for multiple painful conditions, drug discontinuation due to adverse effects was twice as likely for duloxetine compared with placebo (RR 1.96, 95% CI 1.6-2.37). The 120 mg daily dose was similarly effective but not as well tolerated as 60 mg daily.</p><p class="headingAnchor" id="H2659409739"><span class="h4">Venlafaxine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">Venlafaxine</a> is an SNRI with a similar spectrum of clinical activity as <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>. Although not as well studied as duloxetine in patients with diabetic neuropathy, the available data suggest that venlafaxine is a reasonable alternative to duloxetine for this purpose [<a href="#rid1">1</a>].</p><p>The recommended starting dose of <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> in patients with diabetic neuropathy is 37.5 mg daily, titrated gradually upwards to a usual effective dose range of 75 to 225 mg daily [<a href="#rid1">1</a>]. In the largest randomized trial, pain scores declined gradually from week 1 to 6, reaching a maximum reduction at week 6 [<a href="#rid28">28</a>].</p><p>Common side effects of <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> include nausea, somnolence, dizziness, dyspepsia, insomnia, diaphoresis, and sexual dysfunction. Increased blood pressure and heart rate occur more often with venlafaxine than placebo. Like <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, venlafaxine can exacerbate restless legs syndrome and should not be taken with other serotonin or norepinephrine uptake inhibitors (including tricyclic drugs). (See  <a class="medical medical_review" href="/z/d/html/4892.html" rel="external">"Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Venlafaxine'</a>.)</p><p>A 2015 systematic review identified six randomized trials of <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> versus placebo or an active comparator for neuropathic pain in a total of 460 patients, most having painful diabetic neuropathy [<a href="#rid29">29</a>]. All the included trials showed some benefit for venlafaxine, but all had limitations that could cause an overestimation of effect size. In the largest trial, extended-release (ER) venlafaxine was evaluated in 244 patients with painful diabetic neuropathy [<a href="#rid28">28</a>]. For venlafaxine ER at higher doses (150 to 225 mg daily), a 50 percent or greater reduction in pain at 12 weeks was more likely with venlafaxine than placebo (56 versus 34 percent). The effects of the 75 mg daily dose were smaller and not statistically significant.</p><p class="headingAnchor" id="H9"><span class="h4">Tricyclic drugs</span><span class="headingEndMark"> — </span>Several TCA drugs (<a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>) are effective for neuropathic pain in patients with diabetic neuropathy and can be used cautiously for this purpose, with attention to their higher risk of serious side effects [<a href="#rid1">1,17</a>]. Tricyclics are thought to impact the central perception of pain via effects on synaptic monoamines. Patients should be screened for heart disease before use. (See  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Baseline testing and monitoring for safety'</a>.)</p><p>The starting dose of <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> or <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> is 10 to 25 mg/day with a gradual titration up to 100 mg/day if painful symptoms persist. <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">Desipramine</a> is begun at 25 mg/day, and the dose can gradually be increased to a maximum of 200 mg/day over a few weeks. Both amitriptyline and desipramine should be given at bedtime because of their sedating properties. The therapeutic effect of tricyclic drugs for pain usually occurs sooner (within six weeks) and at lower doses than is typical when these drugs are given for the treatment of depression.</p><p>Common side effects of TCAs include dry mouth and somnolence. Urinary retention may occur, especially those with enlarged prostates. We frequently substitute <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> for <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> if anticholinergic side effects are a problem, and some experts use nortriptyline as first line because it has fewer anticholinergic side effects than amitriptyline. Importantly, TCAs are contraindicated in patients with cardiac disease (either conduction system or ischemic). Similar to the SNRIs, they should not be given in combination with other serotonergic drugs.</p><p>Supporting data for tricyclic drugs include results of several randomized controlled trials in patients with painful diabetic neuropathy [<a href="#rid19">19,30-33</a>]. In part because these are older drugs, the number and size of the trials are generally small, and <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> is the most studied agent. Examples of comparative trials illustrating the effects and tolerability of tricyclics in the diabetes population include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In two randomized blinded crossover trials in 84 patients with painful diabetic neuropathy, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> and <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> were equally effective and superior to <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> or placebo [<a href="#rid31">31</a>]. The benefit of the tricyclic drugs was noted within two weeks and continued to increase at six weeks. Desipramine had somewhat fewer side effects than amitriptyline, particularly dry mouth. The average effective dose, titrated over six weeks to achieve control of symptoms, was 111 mg/day for desipramine and 105 mg/day for amitriptyline. There was no correlation between relief of pain, dose, or plasma drug concentrations, suggesting that the clinical response and tolerability of side effects are the best guides to dose titration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized, blinded crossover trial in 58 patients with painful diabetic neuropathy that compared <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> (10 to 50 mg daily) and <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> (20 to 60 mg daily) given at bedtime found an improvement in pain with both medications compared with pretreatment baseline [<a href="#rid19">19</a>]. A good outcome, defined as a median pain score reduction of &gt;50 percent, was reported at a similar rate for amitriptyline and duloxetine (55 versus 59 percent). Dry mouth was more frequent with amitriptyline compared with duloxetine (55 versus 24 percent), while constipation was nonsignificantly more frequent with duloxetine (37 versus 17 percent).</p><p></p><p class="headingAnchor" id="H235925"><span class="h4">Pregabalin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">Pregabalin</a> is an effective first-line alternative to the antidepressant medications reviewed above in patients with painful diabetic neuropathy [<a href="#rid1">1,17</a>]. It is an alpha-2-delta ligand antiseizure medication that is structurally related to <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. The pain modulatory effect is thought to relate to presynaptic inhibition of the release of excitatory neurotransmitters including glutamate, substance P, and calcitonin gene-related peptide (CGRP) [<a href="#rid34">34,35</a>].</p><p>A typical starting dose of <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> for diabetic neuropathy is 75 to 150 mg per day. The immediate-release formulation is given in two or three divided doses, and a once-daily extended-release preparation is also available (165 mg of extended-release is equivalent to 150 mg of immediate-release). Most trials have used a starting dose of 150 mg per day [<a href="#rid36">36</a>]. The dose can be titrated in increments of 75 mg per day every three to seven days. A total daily dose of 300 mg is the maximum dose approved by the FDA for diabetes-associated neuropathic pain, although some patients may require 450 mg per day. The FDA has approved doses of pregabalin of up to 600 mg per day for other indications. Higher doses are generally less well tolerated and may have limited additional efficacy.</p><p>Common adverse effects include dizziness, somnolence, peripheral edema, and weight gain. The incidence of clinically meaningful weight gain (defined as a ≥7 percent weight increase from baseline to endpoint) was approximately 2 to 4 percent in trials of <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> in patients with diabetic neuropathy, without effects on glucose control [<a href="#rid36">36</a>].</p><p>A 2019 systematic review identified eight randomized trials of <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> for painful diabetic neuropathy in a total of 2320 patients [<a href="#rid37">37</a>]. For pregabalin 300 mg per day, a 50 percent or greater reduction in pain was more likely with pregabalin than placebo (31 versus 24 percent; RR 1.3, 95% CI 1.2-1.5). A higher dose (600 mg per day) was studied in two trials and was also more effective than placebo (41 versus 28 percent). There were no differences in the rate of discontinuation for adverse effects at any dose level compared with placebo. In a separate meta-analysis, the median time to a sustained 1-point improvement on an 11-point pain score for pregabalin (at 150, 300, and 600 mg) and placebo was 13, 5, 4, and 60 days, respectively [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H12"><span class="h4">Gabapentin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> has a similar spectrum of clinical activity and side effects as <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> and is a reasonable, sometimes lower-cost alternative to pregabalin when an antiseizure drug is favored for first-line therapy [<a href="#rid1">1</a>].</p><p>Typical starting doses for <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> are 100 to 300 mg one to three times daily; the drug can be titrated slowly up to a usual effective dose of 900 to 3600 mg daily in three divided doses [<a href="#rid1">1</a>]. The major side effects of gabapentin are somnolence, dizziness, and ataxia.</p><p>In a systematic review that identified six trials in a total of 1277 patients with painful diabetic neuropathy, the proportion of patients achieving at least a 50 percent pain intensity reduction was higher with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> (dosed at ≥1200 mg daily) compared with placebo (38 versus 21 percent; RR 1.9, 95% CI 1.5-2.3) [<a href="#rid38">38</a>]. Individual trials were small but showed consistent effects.</p><p class="headingAnchor" id="H19"><span class="h2">Inadequate response to initial therapy</span><span class="headingEndMark"> — </span>None of the first-line choices are universally effective or tolerated, even with appropriate titration. The time to peak response varies across medications, but, in general, a two- to three-month trial is typically required to titrate to effect and gauge response to initial therapy [<a href="#rid17">17</a>].</p><p>For patients who do not improve on the first medication with appropriate titration, we suggest either adding a second first-line drug from a different medication class or switching to an alternative medication among the first-line options discussed above [<a href="#rid1">1</a>]. A common combination strategy is <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> with <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, although other combinations are reasonable as well depending on individual patient factors.</p><p>Results from multiple trials suggest that the treatment of neuropathic pain with combinations of drugs from different medication classes is modestly more effective than monotherapy. In a multicenter crossover trial of 130 patients with painful diabetic neuropathy that assessed the effect of multiple strategies for adding a second agent to initial monotherapy, combination therapy provided a greater reduction in pain than monotherapy [<a href="#rid39">39</a>]. Patients were given initial monotherapy with <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, or <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>. Those who did not respond to initial monotherapy at six weeks were given a second agent from a different pharmacologic class. Combination strategies consisting of pregabalin added to amitriptyline, amitriptyline added to pregabalin, and pregabalin added to duloxetine were all similarly effective in providing pain relief when assessed at 16-week follow-up. In another single-center trial of 47 patients, the combination of <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> was also found to be more effective than either agent alone for reducing the mean intensity of daily pain during week 4 of treatment at the maximum tolerated daily dose (mean, nortriptyline 50 mg and gabapentin 2180 mg in combination) [<a href="#rid40">40</a>].</p><p>For patients who do not tolerate any of these medications or who prefer nonpharmacologic therapies, we discuss <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> cream, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> patch, alpha-lipoic acid (ALA), transcutaneous electrical nerve stimulation (TENS), and spinal cord stimulation. (See <a class="local">'Topical therapies or neuromodulation'</a> below and <a class="local">'Possibly effective'</a> below.)</p><p class="headingAnchor" id="H1035158088"><span class="h2">Topical therapies or neuromodulation</span><span class="headingEndMark"> — </span>For patients who do not respond to or tolerate first-line medications for neuropathic pain, topical therapies and neuromodulatory approaches with some evidence of benefit in diabetic neuropathy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capsaicin</strong> – <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">Capsaicin</a> cream (0.075% applied topically four times daily) can be used on its own or added to first-line medications for patients with a partial response or intolerance of higher doses. It is also available in gel, liquid, and lotion formulations for topical application. Local burning and skin irritation can occur, but this becomes less of a problem with continued use. Nevertheless, many patients are unable to tolerate the local burning pain, which is exacerbated by contact with warm water and hot weather [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">The high-concentration <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> (8%) patch is FDA approved to treat painful diabetic neuropathy at the feet [<a href="#rid41">41</a>]. Patches are administered by a health care professional as a single 30-minute application, and patients are monitored for up to two hours following treatment. The treatment may be repeated at three months for patients with partial or temporary relief after the initial application. Progressive improvements may be achieved with subsequent applications [<a href="#rid42">42</a>]. However, patients may report localized erythema, pain, or post-application sensory loss with use. Patches must be handled carefully, and the application site is usually pretreated with a local anesthetic such as topical <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">Capsaicin</a> is a naturally occurring component of many hot peppers and causes analgesia through local depletion of substance P. In randomized trials in patients with painful diabetic neuropathy, capsaicin has been associated with modest but statistically significant improvement in pain compared with placebo [<a href="#rid22">22,43-46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lidocaine</strong><strong> patches</strong> – Limited evidence suggests that application of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> patches (5%) can improve pain in patients with painful diabetic neuropathy [<a href="#rid47">47</a>]. Patches may remain in place for no more than 12 hours in any 24-hour period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrical nerve stimulation </strong>– Although data are limited, a 2010 statement from the American Academy of Neurology (AAN) assessing the use of TENS for pain in neurologic disorders concluded that TENS is probably effective for reducing pain from diabetic neuropathy [<a href="#rid48">48</a>], based upon the following evidence.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One trial assigned 31 patients with chronic painful diabetic neuropathy to either TENS or sham treatment to the legs for 30 minutes daily for four weeks [<a href="#rid49">49</a>]. Symptomatic improvement (of at least one grade on a unique 0 to 5 scale) occurred in 15 of 18 patients (83 percent) with TENS treatment, compared with 5 of 13 patients (38 percent) who received sham treatment (odds ratio 6, 95% CI 1.1-33.4) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another trial evaluated 19 patients with mild to moderate symptomatic diabetic polyneuropathy [<a href="#rid50">50</a>]. Compared with sham treatment, active treatment with TENS led to a statistically significant reduction in total symptom score at 6 and 12 weeks. In addition, TENS therapy was associated with a statistically significant but modest improvement in pain on the visual analog scale at six weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal cord stimulation</strong> – Small studies have reported symptom improvement with electrical pulsed stimulation of percutaneously implanted epidural electrodes corresponding to the distribution of pain [<a href="#rid51">51-53</a>]. In an open-label trial of 216 patients with refractory painful diabetic neuropathy treated with medical therapy, those assigned to high-frequency spinal cord stimulation were likelier to report at least 50 percent pain reduction at three months than those assigned to medical therapy alone [<a href="#rid54">54</a>]. A systematic review of three trials and five observational studies found moderate-quality evidence to support the use of spinal cord stimulation for pain relief in diabetic neuropathy of the lower extremities [<a href="#rid55">55</a>]. Future studies with effective sham controls are required to understand the therapeutic benefit of and help identify optimal patients for spinal cord stimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acupuncture</strong> – Pilot studies indicate that acupuncture may be an effective nonpharmacologic option for painful neuropathy when delivered individually [<a href="#rid56">56-58</a>] or in a group setting [<a href="#rid59">59</a>]. A meta-analysis of 25 randomized trials in China concluded that acupuncture improves global symptoms of painful diabetic neuropathy compared with B vitamins (RR 1.3 to 1.6) or no treatment (RR 1.6), with no adverse events reported [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H2934690381"><span class="h2">Other therapies</span></p><p class="headingAnchor" id="H4294771562"><span class="h3">Possibly effective</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-lipoic acid (ALA)</strong> – For patients who are refractory to or intolerant of first-line pharmacotherapies and interested in a nutritional supplement approach, we offer a trial of oral ALA (600 mg daily). ALA is an antioxidant with the potential to diminish oxidative stress, improve the underlying pathophysiology of neuropathy, and reduce pain. (See  <a class="medical medical_review" href="/z/d/html/5279.html" rel="external">"Pathogenesis of diabetic polyneuropathy"</a>.)</p><p></p><p class="bulletIndent1">Several prospective, placebo-controlled trials have examined short-term use of ALA (either intravenous or oral) in patients with painful diabetic neuropathy [<a href="#rid61">61-64</a>]. In an initial trial, daily intravenous ALA for three weeks was associated with reduced pain, paresthesia, and numbness compared with placebo infusions [<a href="#rid62">62</a>]. In a second trial, oral ALA (600, 1200, or 1800 mg daily) versus placebo was studied in 181 patients with diabetes and symptomatic distal symmetric polyneuropathy (DSPN) [<a href="#rid64">64</a>]. All three doses of oral ALA treatment were associated with a reduction in the neuropathy total symptom score (a summation of stabbing pain, burning pain, paresthesia, and asleep numbness) compared with placebo. The benefit of ALA did not differ by dose. A ≥50 percent reduction in neuropathic symptoms was observed in 50 to 62 percent of patients treated with ALA versus 26 percent with placebo. Doses higher than 600 mg daily were limited by increasing adverse events (nausea, vomiting, and vertigo) without increasing efficacy. Confidence in the findings is limited by the short duration of this trial. Limited available data on ALA used over a longer duration (ie, &gt;6 months) suggest the therapy provides minimal sustained benefit on improving symptoms or nerve damage [<a href="#rid65">65</a>]. However, these data are limited by high attrition bias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproic acid</a> – Valproate (500 to 1200 mg daily) was effective for reducing pain in diabetic neuropathy in two small placebo-controlled trials from a single center [<a href="#rid66">66,67</a>]. Larger confirmatory studies have not been performed, and the gabapentinoids are generally safer and require less monitoring. Valproate should not be used in patients with liver disease. It has well-recognized teratogenic effects and should be avoided in females of childbearing age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbamazepine</strong> – <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> has a potential role in patients who have failed standard options based on its efficacy in the treatment of trigeminal neuralgia as well as historical reports in patients with diabetic neuropathy [<a href="#rid68">68,69</a>]. Contemporary data are lacking, however.</p><p></p><p class="headingAnchor" id="H1896551602"><span class="h3">Not recommended</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioids</strong> – We avoid the use of opioids for the treatment of painful diabetic neuropathy because of the lack of evidence regarding long-term effectiveness and because of the potential for tolerance, addiction, and overdose. We acknowledge that <a class="drug drug_general" data-topicid="9511" href="/z/d/drug information/9511.html" rel="external">tapentadol</a> has an FDA indication for diabetic neuropathy and that the 2017 American Diabetes Association (ADA) guidelines state that <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a> or tapentadol may be used as the "last-line" therapy prior to referral to a pain clinic [<a href="#rid1">1</a>]. However, a more recent systematic review on generalized treatment of pain suggests that the use of chronic opioid therapy has limited benefit and carries clear medical risk [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">This newer statement is supported by an earlier 2009 systematic review of opioids for chronic noncancer pain, which found a paucity of evidence regarding long-term effectiveness and risks of such treatment, including the potential for opioid abuse, addiction, and overdose [<a href="#rid71">71</a>]. Similarly, a 2013 systematic review noted that the available randomized controlled trials of opioids for neuropathic pain did not clearly address the issues of abuse and addiction [<a href="#rid72">72</a>]. In a cohort study of over 9900 patients prescribed long-term opioid therapy for nonmalignant pain, the use of higher-dose regimens was associated with an increased risk of opioid overdose [<a href="#rid73">73</a>]. Because of these issues, we do not use opioids for treatment of painful diabetic neuropathy. A referral to a pain clinic is suggested for patients whose pain is unresponsive to conventional therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> – A systematic review that analyzed data from three randomized trials concluded that topiramate is not effective for painful diabetic polyneuropathy [<a href="#rid74">74</a>]. </p><p></p><p class="headingAnchor" id="H1342887139"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116787.html" rel="external">"Society guideline links: Neuropathy"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a>.)</p><p class="headingAnchor" id="H23021346"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15648.html" rel="external">"Patient education: Nerve damage caused by diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/82819.html" rel="external">"Patient education: Neuropathic pain (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1746.html" rel="external">"Patient education: Diabetic neuropathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H237049"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of complications</strong> – Established, symptomatic diabetic neuropathy is generally not reversible, and management aims to slow further progression and prevent complications, including diabetic foot ulcers, arthropathy, and falls. (See <a class="local">'Preventive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial symptomatic therapies</strong> – Effective pharmacotherapy options for patients with painful diabetic neuropathy include the following (see <a class="local">'Initial pharmacotherapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serotonin-norepinephrine reuptake inhibitors (<a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Tricyclic antidepressants (<a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Gabapentinoid antiseizure medications (<a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>)</p><p></p><p class="bulletIndent1">Each of these classes of agent have been shown to be more effective than placebo in randomized trials, and limited comparative data suggest that efficacy is similar across agents. </p><p></p><p class="bulletIndent1">Selection of a specific agent should be individualized. In practice, comorbidities and concurrent medications often favor one class or another (ie, an antidepressant or a gabapentinoid antiseizure medication)  (<a class="graphic graphic_table graphicRef126209" href="/z/d/graphic/126209.html" rel="external">table 2</a>). The narrower choice within a class is influenced by the patient's age, preferences with regard to dosing frequency, side effects, and cost/formulary considerations. (See <a class="local">'Choice of agent'</a> above and <a class="local">'Administration and efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative therapeutic options</strong> – None of the first-line choices are universally effective or tolerated, even with appropriate titration. A two- to three-month trial is generally required to titrate to effect and assess response to initial therapy. (See <a class="local">'Inadequate response to initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients who do not respond to or tolerate the initial drug, we try an alternative first-line agent or use a combination of drugs from different classes. (See <a class="local">'Inadequate response to initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who do not tolerate any of the first-line medications and who prefer topical or nonpharmacologic therapies, we discuss <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> cream, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> patch, alpha-lipoic acid, transcutaneous electrical nerve stimulation, and spinal cord stimulation. (See <a class="local">'Topical therapies or neuromodulation'</a> above and <a class="local">'Possibly effective'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We avoid use of opioids for the treatment of painful diabetic neuropathy because of the lack of evidence regarding long-term effectiveness; the potential for tolerance, addiction, and overdose; and the availability of multiple safer alternative therapies. (See <a class="local">'Not recommended'</a> above.)</p><p></p><p class="headingAnchor" id="H4019319598"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David K McCulloch, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40:136.</a></li><li><a class="nounderline abstract_t">Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38:869.</a></li><li><a class="nounderline abstract_t">Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37:31.</a></li><li><a class="nounderline abstract_t">Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; :CD007543.</a></li><li><a class="nounderline abstract_t">Cortez M, Singleton JR, Smith AG. Glucose intolerance, metabolic syndrome, and neuropathy. Handb Clin Neurol 2014; 126:109.</a></li><li><a class="nounderline abstract_t">Bönhof GJ, Herder C, Strom A, et al. Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. Endocr Rev 2019; 40:153.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41:S38.</a></li><li><a class="nounderline abstract_t">Streckmann F, Balke M, Cavaletti G, et al. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Med 2022; 52:1043.</a></li><li><a class="nounderline abstract_t">Müller-Stich BP, Fischer L, Kenngott HG, et al. Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization--results of a prospective cohort study (DiaSurg 1 study). Ann Surg 2013; 258:760.</a></li><li><a class="nounderline abstract_t">O'Brien R, Johnson E, Haneuse S, et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. Ann Intern Med 2018; 169:300.</a></li><li><a class="nounderline abstract_t">Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101:1754.</a></li><li><a class="nounderline abstract_t">Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29:1518.</a></li><li><a class="nounderline abstract_t">Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009; 10:393.</a></li><li><a class="nounderline abstract_t">Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 1988; 11:34.</a></li><li><a class="nounderline abstract_t">Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med 2014; 161:639.</a></li><li class="breakAll">Dy SM, Bennett WL, Sharma R, et al. Preventing complications and treating symptoms of diabetic peripheral neuropathy. Comparative Effectiveness Review No. 187. AHRQ Publication No. 17-EHC005-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. https://effectivehealthcare.ahrq.gov/ehc/products/612/2436/diabetic-neuropathy-report-170324.pdf (Accessed on April 06, 2017).</li><li><a class="nounderline abstract_t">Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology 2022; 98:31.</a></li><li><a class="nounderline abstract_t">Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012; 35:2451.</a></li><li><a class="nounderline abstract_t">Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011; 34:818.</a></li><li><a class="nounderline abstract_t">Boulton AJ. Is duloxetine more effective than amitriptyline for painful diabetic neuropathy? Curr Diab Rep 2011; 11:230.</a></li><li><a class="nounderline abstract_t">Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy. Drug Des Devel Ther 2019; 13:1985.</a></li><li><a class="nounderline abstract_t">Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76:1758.</a></li><li><a class="nounderline abstract_t">Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11:1475.</a></li><li><a class="nounderline abstract_t">Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109.</a></li><li><a class="nounderline abstract_t">Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6:346.</a></li><li><a class="nounderline abstract_t">Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67:1411.</a></li><li><a class="nounderline abstract_t">Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; :CD007115.</a></li><li><a class="nounderline abstract_t">Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697.</a></li><li><a class="nounderline abstract_t">Gallagher HC, Gallagher RM, Butler M, et al. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev 2015; :CD011091.</a></li><li><a class="nounderline abstract_t">Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37:589.</a></li><li><a class="nounderline abstract_t">Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250.</a></li><li><a class="nounderline abstract_t">Kvinesdal B, Molin J, Frøland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251:1727.</a></li><li><a class="nounderline abstract_t">Vrethem M, Boivie J, Arnqvist H, et al. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997; 13:313.</a></li><li><a class="nounderline abstract_t">Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280:107.</a></li><li><a class="nounderline abstract_t">Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105:133.</a></li><li><a class="nounderline abstract_t">Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448.</a></li><li><a class="nounderline abstract_t">Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019; 1:CD007076.</a></li><li><a class="nounderline abstract_t">Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; :CD007938.</a></li><li><a class="nounderline abstract_t">Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet 2022; 400:680.</a></li><li><a class="nounderline abstract_t">Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374:1252.</a></li><li class="breakAll">QUTENZA (capsaicin) patch prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf (Accessed on October 22, 2021).</li><li><a class="nounderline abstract_t">Freynhagen R, Argoff C, Eerdekens M, et al. Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications. Pain Med 2021; 22:2324.</a></li><li><a class="nounderline abstract_t">Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes Care 1992; 15:159.</a></li><li><a class="nounderline abstract_t">Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med 1991; 151:2225.</a></li><li><a class="nounderline abstract_t">Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992; 15:8.</a></li><li><a class="nounderline abstract_t">Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. J Pain 2017; 18:42.</a></li><li><a class="nounderline abstract_t">Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914.</a></li><li><a class="nounderline abstract_t">Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:173.</a></li><li><a class="nounderline abstract_t">Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20:1702.</a></li><li><a class="nounderline abstract_t">Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004; 17:163.</a></li><li><a class="nounderline abstract_t">de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain 2014; 155:2426.</a></li><li><a class="nounderline abstract_t">Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care 2014; 37:3016.</a></li><li><a class="nounderline abstract_t">Sills S. Treatment of painful polyneuropathies of diabetic and other origins with 10 kHz SCS: a case series. Postgrad Med 2020; 132:352.</a></li><li><a class="nounderline abstract_t">Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol 2021; 78:687.</a></li><li><a class="nounderline abstract_t">Xu L, Sun Z, Casserly E, et al. Advances in Interventional Therapies for Painful Diabetic Neuropathy: A Systematic Review. Anesth Analg 2022; 134:1215.</a></li><li><a class="nounderline abstract_t">Ahn AC, Bennani T, Freeman R, et al. Two styles of acupuncture for treating painful diabetic neuropathy--a pilot randomised control trial. Acupunct Med 2007; 25:11.</a></li><li><a class="nounderline abstract_t">Garrow AP, Xing M, Vere J, et al. Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT. Acupunct Med 2014; 32:242.</a></li><li><a class="nounderline abstract_t">Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998; 39:115.</a></li><li><a class="nounderline abstract_t">Chao MT, Schillinger D, Nguyen U, et al. A Randomized Clinical Trial of Group Acupuncture for Painful Diabetic Neuropathy Among Diverse Safety Net Patients. Pain Med 2019; 20:2292.</a></li><li><a class="nounderline abstract_t">Chen W, Yang GY, Liu B, et al. Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PLoS One 2013; 8:e73764.</a></li><li><a class="nounderline abstract_t">Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999; 16:1040.</a></li><li><a class="nounderline abstract_t">Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26:770.</a></li><li><a class="nounderline abstract_t">Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21:114.</a></li><li><a class="nounderline abstract_t">Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29:2365.</a></li><li><a class="nounderline abstract_t">Baicus C, Purcarea A, von Elm E, et al. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database Syst Rev 2024; 1:CD012967.</a></li><li><a class="nounderline abstract_t">Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurol Scand 2002; 106:248.</a></li><li><a class="nounderline abstract_t">Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004; 97:33.</a></li><li><a class="nounderline abstract_t">Rull JA, Quibrera R, González-Millán H, Lozano Castañeda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969; 5:215.</a></li><li><a class="nounderline abstract_t">Chakrabarti AK, Samantaray SK. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy. Aust N Z J Med 1976; 6:565.</a></li><li><a class="nounderline abstract_t">Busse JW, Wang L, Kamaleldin M, et al. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. JAMA 2018; 320:2448.</a></li><li><a class="nounderline abstract_t">Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10:147.</a></li><li><a class="nounderline abstract_t">McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev 2013; :CD006146.</a></li><li><a class="nounderline abstract_t">Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152:85.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Lunn MP, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013; :CD008314.</a></li></ol></div><div id="topicVersionRevision">Topic 5280 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999003" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diabetic Neuropathy: A Position Statement by the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8526459" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24356595" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696371" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Enhanced glucose control for preventing and treating diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25410218" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Glucose intolerance, metabolic syndrome, and neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30256929" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29222375" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964950" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Exercise and Neuropathy: Systematic Review with Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979278" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization--results of a prospective cohort study (DiaSurg 1 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083761" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26900641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801572" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207236" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3338378" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25364885" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25364885" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34965987" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22991449" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21355098" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597896" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is duloxetine more effective than amitriptyline for painful diabetic neuropathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31354243" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482920" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15892657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15927394" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Duloxetine vs. placebo in patients with painful diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16266355" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060567" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24385423" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288411" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26298465" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Venlafaxine for neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2436092" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1560801" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366276" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Imipramine treatment of painful diabetic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430812" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686389" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14499429" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356405" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30673120" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pregabalin for neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771480" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gabapentin for chronic neuropathic pain and fibromyalgia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36007534" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796802" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796802" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33871648" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1547671" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1953227" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1737545" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27746370" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210530" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042705" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9353612" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334794" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180016" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25216508" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073352" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of painful polyneuropathies of diabetic and other origins with 10 kHz SCS: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33818600" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051958" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Advances in Interventional Therapies for Painful Diabetic Neuropathy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17641562" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Two styles of acupuncture for treating painful diabetic neuropathy--a pilot randomised control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657491" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9597381" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31127837" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Randomized Clinical Trial of Group Acupuncture for Painful Diabetic Neuropathy Among Diverse Safety Net Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069229" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10656234" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610036" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14984445" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065669" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38205823" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Alpha-lipoic acid for diabetic peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12371916" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14702509" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4902717" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1071542" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561481" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187891" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23986501" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Opioids for neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083827" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Opioid prescriptions for chronic pain and overdose: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23996081" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Topiramate for neuropathic pain and fibromyalgia in adults.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
